Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Targeted Primaquine Mass Treatment for P. vivax in Myanmar
NCT06392152Active, not recruiting
- Start
- Jul 2019
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of primaquine in Plasmodium vivax malaria (2 arms). Primary endpoints: Infection prevalence at 3-month intervals and Monthly malaria incidence up to 24 months. Started Jul 2019; status: active, not recruiting.
02
Drugs
primaquine
03
Conditions
Plasmodium vivax malaria
Beyond the preview
Go deeper on NCT06392152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06392152.